Comparative Pharmacology
Head-to-head clinical analysis: NURTEC ODT versus QULIPTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NURTEC ODT versus QULIPTA.
NURTEC ODT vs QULIPTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CGRP receptor antagonist; blocks binding of calcitonin gene-related peptide to its receptor, inhibiting vasodilation and neurogenic inflammation in trigeminovascular system.
QULIPTA (atogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist. It competitively blocks the binding of CGRP to its receptor, thereby inhibiting CGRP-mediated vasodilation and pain transmission involved in migraine pathophysiology.
75 mg orally once daily as needed, not to exceed 75 mg in 24 hours.
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life of approximately 11 hours, supporting twice-daily dosing for migraine prevention.
Terminal elimination half-life is approximately 21 hours, supporting once-daily dosing.
Roughly 75% of dose excreted in feces (as unchanged drug and metabolites), 24% in urine (mostly metabolites, <1% unchanged).
Approximately 60% of the dose is excreted in feces (as unchanged drug and metabolites) and 40% in urine (primarily as metabolites, with <1% unchanged).
Category C
Category C
CGRP Antagonist
CGRP Antagonist